Buscar

Estamos realizando la búsqueda. Por favor, espere...

In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and/or resistant to linezolid or glycopeptides

Abstract: Introduction The aim was to investigate the in vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci (CoNS) isolates with reduced susceptibility to daptomycin or resistant to linezolid and/or glycopeptides. Methods A total of 228 CoNS were tested using the Vitek-2 AST-626 cards (bioMérieux) and MIC of daptomycin, linezolid, vancomycin and teicoplanin were confirmed by Etest Strips (bioMérieux). Susceptibility testing for ceftobiprole and dalbavancin were performed by CLSI broth microdilution methodology. Results were interpreted according to 2021 EUCAST clinical breakpoints. Results Ceftobiprole and dalbavancin were active against 96.0% and 93.0% of CoNS, respectively, MIC90 were 2 and 0.125 mg/L. MICs of ceptobiprole were higher against S. hominis and S. haemolyticus (MIC90 4 mg/L). Dalbavancin exhibited higher MICs against S. haemolyticus and CoNS with reduced susceptibility to daptomycin and resistant to teicoplanin. Conclusion Ceftobiprole and dalbavancin demonstrated a high in vitro activity against our collection of CoNS isolates.

 Fuente: Enfermedades Infecciosas y Microbiología Clínica, 2023, 41, 567-570

 Editorial: Doyma

 Año de publicación: 2023

 Nº de páginas: 4

 Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.eimce.2022.06.017

 ISSN: 0213-005X,1578-1852

 Url de la publicación: https://doi.org/10.1016/j.eimce.2022.06.017

Autoría

VELASCO DE LA FUENTE, SILVIA

MARTA FERNANDEZ MARTINEZ

DANIEL PABLO MARCOS

SILLER, MARÍA

CALVO, JORGE